利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.025 秒)

    ANTIBODY AGAINST HUMAN PROSTAGLANDIN E2 RECEPTOR EP4
    1.
    发明申请
    ANTIBODY AGAINST HUMAN PROSTAGLANDIN E2 RECEPTOR EP4 有权
    针对人PROSTAGLANDIN E2受体EP4的抗体

    公开(公告)号：US20130197199A1

    公开(公告)日：2013-08-01

    申请号：US13876763

    申请日：2011-09-28

    申请人： Kiyoshi Takayama ,  Tomoko Shimizu ,  Yuji Urushibata ,  Yukihiko Sugimoto

    发明人： Kiyoshi Takayama ,  Tomoko Shimizu ,  Yuji Urushibata ,  Yukihiko Sugimoto

    IPC分类号： C07K16/28

    CPC分类号： C07K16/28 ,  C07K16/2869 ,  C07K17/00 ,  C07K2317/24 ,  C07K2317/76 ,  G01N33/88

    摘要： It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.

    摘要翻译： 本发明的目的是提供结合人PGE2受体亚型EP4并抑制EP4的功能的抗体或其功能性片段。 本发明的另一个目的是提供一种包含上述抗体或其功能片段的药物。 用人PGE2受体亚型EP4免疫小鼠，并筛选抑制EP4诱导的细胞内cAMP水平升高的单克隆抗体。 另外，测定得到的单克隆抗体的CDR序列。

    Antibody against human prostaglandin E2 receptor EP4
    2.
    发明授权
    Antibody against human prostaglandin E2 receptor EP4 有权
    抗人前列腺素E2受体EP4的抗体

    公开(公告)号：US09175080B2

    公开(公告)日：2015-11-03

    申请号：US13876763

    申请日：2011-09-28

    申请人： Kiyoshi Takayama ,  Tomoko Shimizu ,  Yuji Urushibata ,  Yukihiko Sugimoto

    发明人： Kiyoshi Takayama ,  Tomoko Shimizu ,  Yuji Urushibata ,  Yukihiko Sugimoto

    IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K17/00 ,  G01N33/88

    CPC分类号： C07K16/28 ,  C07K16/2869 ,  C07K17/00 ,  C07K2317/24 ,  C07K2317/76 ,  G01N33/88

    摘要： It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.

    摘要翻译： 本发明的目的是提供结合人PGE2受体亚型EP4并抑制EP4的功能的抗体或其功能性片段。 本发明的另一个目的是提供一种包含上述抗体或其功能片段的药物。 用人PGE2受体亚型EP4免疫小鼠，并筛选抑制EP4诱导的细胞内cAMP水平升高的单克隆抗体。 另外，测定得到的单克隆抗体的CDR序列。

    Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
    3.
    发明授权
    Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier 有权
    抗人CCR7抗体，杂交瘤，核酸，载体，细胞，药物组合物和抗体固定载体

    公开(公告)号：US08865170B2

    公开(公告)日：2014-10-21

    申请号：US13876265

    申请日：2011-09-27

    申请人： Naoki Nishiguchi ,  Akiyoshi Hirayama ,  Masahiro Furutani ,  Tatsuo Shimizu ,  Kiyoshi Takayama ,  Tomoko Shimizu ,  Kazuya Suzuki

    发明人： Naoki Nishiguchi ,  Akiyoshi Hirayama ,  Masahiro Furutani ,  Tatsuo Shimizu ,  Kiyoshi Takayama ,  Tomoko Shimizu ,  Kazuya Suzuki

    IPC分类号： C07K16/28 ,  A61K31/713 ,  A61K39/00

    CPC分类号： C07K16/2866 ,  A61K31/713 ,  A61K2039/505 ,  C07K2317/70 ,  C07K2317/76

    摘要： The present invention is novel anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibodies useful for treating tissue fibrosis or cancer, and pharmaceutical compositions containing the anti-human-CCR7 antibodies. The invention includes an anti-human-CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77. The invention also includes an anti-human-CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.

    摘要翻译： 本发明是可用于治疗组织纤维化或癌症的新型抗人CC-基质受体-7（抗人CCR7）抗体，以及含有抗人CCR7抗体的药物组合物。 本发明包括与人CCR7的细胞外结构域特异性结合的抗人CCR7抗体，其具有含有SEQ ID NO：7，SEQ ID NO：17，SEQ ID NO：27所示氨基酸序列的重链CDR3， SEQ ID NO：37，SEQ ID NO：47，SEQ ID NO：57，SEQ ID NO：67或SEQ ID NO：77.本发明还包括具有重链CDR 1-3的抗人CCR7抗体， 含有由SEQ ID NO：5-10，15-20,25-30,35-40,45-50,55-60,65-70或75-80表示的氨基酸序列的轻链CDR1-3。 优选地，抗体具有干扰由CCR7配体刺激引起的CCR7依赖性细胞内信号转导机制的活性。

    INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1E
    5.
    发明申请
    INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1E 有权
    CASEIN KINASE 1DELTA和CASEIN KINASE 1E的抑制剂

    公开(公告)号：US20130137730A1

    公开(公告)日：2013-05-30

    申请号：US13816180

    申请日：2011-08-08

    申请人： Masako Okamoto ,  Kiyoshi Takayama

    发明人： Masako Okamoto ,  Kiyoshi Takayama

    IPC分类号： A61K31/4439

    CPC分类号： A61K31/4439 ,  C07D413/14

    摘要： There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1δ and casein kinase 1ε. In addition, the present inhibitor inhibits casein kinase 1δ and casein kinase 1ε, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1δ or casein kinase 1ε is associated. There is further provided a pharmaceutical agent useful for the treatment of particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.An inhibitor of casein kinase 1δ and casein kinase 1ε comprising, as an act ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: wherein X represents a halogen atom (which may be any one of a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom).

    摘要翻译： 提供了对酪蛋白激酶1delta和酪蛋白激酶1epsilon具有抑制活性的新型恶唑酮衍生物。 此外，本发明的抑制剂抑制酪蛋白激酶1delta和酪蛋白激酶1β，因此还提供了可用于治疗和/或预防疾病的药剂，其病理条件是酪蛋白激酶1delta或酪蛋白的激活机制 激酶1epon是相关的。 还提供了用于特别治疗昼夜节律紊乱（包括睡眠障碍），中枢性神经变性疾病和癌症的药剂。 酪蛋白激酶1delta和酪蛋白激酶1β的抑制剂，其包含作为成分的由以下通式（1）表示的恶唑酮衍生物，其盐，其溶剂合物或其水合物：其中X表示卤素原子（ 其可以是氟原子，氯原子，溴原子和碘原子中的任何一个）。

    Clarithromycin or salt thereof for use in the treatment or prevention of pulmonary disease induced by destruction of pulmonary alveoli
    6.
    发明授权
    Clarithromycin or salt thereof for use in the treatment or prevention of pulmonary disease induced by destruction of pulmonary alveoli 有权
    克拉霉素或其盐，用于治疗或预防由肺泡破坏引起的肺部疾病

    公开(公告)号：US08017588B2

    公开(公告)日：2011-09-13

    申请号：US11917845

    申请日：2006-06-21

    申请人： Kiyoshi Takayama

    发明人： Kiyoshi Takayama

    IPC分类号： A61K31/70

    CPC分类号： A61K31/7048

    摘要： For the purpose of treatment and/or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a salt thereof.

    摘要翻译： 为了治疗和/或预防由吸烟，空气污染，有害气体等引起的肺泡破坏引起的肺部疾病的目的，提供了将克拉霉素或其盐施用于 哺乳动物和包含克拉霉素或其盐的药物组合物。

    Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli
    7.
    发明申请
    Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli 审中-公开
    克拉霉素或其盐，用于治疗或预防由肺泡破坏引起的肺部疾病

    公开(公告)号：US20060293261A1

    公开(公告)日：2006-12-28

    申请号：US11165201

    申请日：2005-06-24

    申请人： Kiyoshi Takayama

    发明人： Kiyoshi Takayama

    IPC分类号： A61K31/7048

    CPC分类号： A61K31/7048

    摘要： For the purpose of treatment and/or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a salt thereof.

    摘要翻译： 为了治疗和/或预防由吸烟，空气污染，有害气体等引起的肺泡破坏引起的肺部疾病的目的，提供了将克拉霉素或其盐施用于 哺乳动物和包含克拉霉素或其盐的药物组合物。

    Inhibitor of casein kinase 1delta and casein kinase 1E
    8.
    发明授权
    Inhibitor of casein kinase 1delta and casein kinase 1E 有权
    酪蛋白激酶1delta和酪蛋白激酶1E的抑制剂

    公开(公告)号：US08710231B2

    公开(公告)日：2014-04-29

    申请号：US13816180

    申请日：2011-08-08

    申请人： Masako Okamoto ,  Kiyoshi Takayama

    发明人： Masako Okamoto ,  Kiyoshi Takayama

    IPC分类号： C07D413/00 ,  C07D419/00 ,  C07D409/00 ,  C07D411/00 ,  A61K31/44 ,  A01N43/40

    CPC分类号： A61K31/4439 ,  C07D413/14

    摘要： There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1δ and casein kinase 1ε. In addition, the present inhibitor inhibits casein kinase 1δ and casein kinase 1ε, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1δ or casein kinase 1ε is associated. There is further provided a pharmaceutical agent useful for the treatment of, particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1δ and casein kinase 1ε comprising, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: wherein X represents a halogen atom which is fluorine, chlorine, bromine or iodine.

    摘要翻译： 提供了一种对酪蛋白激酶1δ和酪蛋白激酶1具有抑制活性的新型恶唑酮衍生物。 此外，本发明的抑制剂抑制酪蛋白激酶1δ和酪蛋白激酶1和egr，因此还提供了可用于治疗和/或预防疾病的药剂，其病理条件是酪蛋白激酶1δ或 酪蛋白激酶1 已关联的。 还提供了用于治疗，特别是昼夜节律紊乱（包括睡眠障碍），中枢神经变性疾病和癌症的药剂。 酪蛋白激酶1δ和酪蛋白激酶1的抑制剂 作为活性成分，含有下述通式（1）表示的恶唑酮衍生物，其盐，溶剂化物或其水合物：其中，X表示氟，氯，溴或碘的卤素原子。